VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 9, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received further clinical testing results from BioScience Laboratories, Inc. for the T36® formulation ("T36®"). Complete efficacy was achieved against Mycobacterium avium and Mycobacterium terrae by T36® within 5 minutes, the shortest time required by the FDA, Health Canada and the European Medicines Agency ("EMA"). Mycobacteria are the most difficult bacteria to kill and are used as benchmark organisms to test the effectiveness of anti-microbial formulations.
